Skip to main content
×
Home
    • Aa
    • Aa

Patient Access to Experimental Drugs and AIDS Clinical Trial Designs: Ethical Issues

  • Udo Schüklenk (a1) and Carlton Hogan (a2)
Abstract

Today's clinical AIDS research is in trouble. Principal investigators are confronted with young and frequently highly knowledgeable patients. Many of these people with AIDS (PWAs) are often unwilling to adhere to the trial protocols. These PWAs believe they are ethically justified in breaching trial protocols because they do not consider themselves true volunteers in such trials. PWAs argue that they do not really volunteer because existing legislation prevents them from buying and using experimental drugs or from testing alternative treatment strategies. Their only access to such agents is participation in clinical trials.

Copyright
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

M Delaney . The case for patient access to experimental therapies. Journal of Infectious Diseases 1989;159:416–9.

MA Fischl , DD Richman , MH Grieco , The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 1987;317:185–91

MA Sande , CCJ Arpener , CG Obiss , Antiretroviral therapy for adult HIV-infected patients recommendations from a state-of-the-art conference. Journal of the American Medical Association 1993;270:2583–9.

The Lancet 1993;342:1311–2.

B Freedman . Equipoise and the ethics of clinical research. New England Journal of Medicine 1987;317:141–5.

KJ Rothman , KB Michels . The continuing unethical use of placebo controls. New England Journal of Medicine 1994;331:394–8.

S Hellman , DS Hellman . Of mice but not men: problems of the randomized clinical trial. New England Journal of Medicine 1991;324:1585–9.

RD Mohr . AIDS, gays and state coercion. Bioethics 1987;1:3550.

AF Shorr . AIDS and the FDA: an ethical case for limiting patient access to new medical therapies. IRB: A Review of Human Subjects Research 1992; 14(4): 15.

P Singer . Practical Ethics. Cambridge, United Kingdom: Cambridge University Press, 1993.

B Minogue , G Palmer-Fernandez , L Udell , BN Waller . Individual autonomy and the double-blind controlled experiment. Journal of Medicine and Philosophy 1995;20:4355.

TR Fleming . Surrogate markers in AIDS and cancer trials. Statistics in Medicine 1994;13:1423–35.

S Ellenberg . Discussion of “surrogate markers in AIDS and cancer trials.” Statistics in Medicine 1994;13:1437–40.

On stopping a trial before its time. Lancet 1993;342:1311.

SS Ellenberg , D Finkelstein , DA Schoenfeld . Statistical issues arising in AIDS clinical trials. Journal of the American Statistical Association 1992;87:573–6.

DP Byar , DA Choenfeld , SB Reen , Design considerations for AIDS trials. New England Journal of Medicine 1990;323:1343–8.

SB Green Issues in the design of drug trials for AIDS. Controlled Clinical Trials 1990;11:80–7.

D Schwarz , J Lellouch . Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Disease 1967;20:637–48.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Cambridge Quarterly of Healthcare Ethics
  • ISSN: 0963-1801
  • EISSN: 1469-2147
  • URL: /core/journals/cambridge-quarterly-of-healthcare-ethics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 3 *
Loading metrics...

Abstract views

Total abstract views: 139 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 28th June 2017. This data will be updated every 24 hours.